Fresh hotcakes! Practice-changing articles that you need to know: semaglutide for weight loss; metronidazole plus a fluoroquinolone versus amoxicillin/clavulanic acid for uncomplicated diverticulitis; and the perioperative risks of COVID19. We’re joined by Dr. Adnan Khan (Chief resident, VCU Internal Medicine Residency) and our fearless leader of critical appraisal, internist/epidemiologist, Rahul Ganatra MD, MPH, @rbganatra (VA Boston).
Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | firstname.lastname@example.org | Free CME!
This episode is supported by Panacea Financial, digital banking built for doctors, by doctors. At Panacea Financial you can have your own free personal banker and a support team that works around the clock- just like you do. Open your free checking account today at panaceafinancial.com
Panacea Financial, a Division of Sonabank, Member FDIC
MKSAP® is the most trusted resource for lifelong learning and Board prep for internal medicine physicians and residents. Learn more at acponline.org/mksap19 and use promo code CURB2021 at check out.
The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org.
Question: How safe and effective is once-weekly injected semaglutide (plus weight-loss counseling) for achieving weight loss among overweight or obese adults without diabetes?
Comparison: 1961 Participants were randomized to receive semaglutide 2.4mg once weekly or placebo with lifestyle interventions for 68 weeks. The coprimary endpoints were percentage weight change from baseline to week 68 and reduction of body weight by 5% or more.
Results: The intention-to-treat analysis for the endpoint of mean weight change was -14.85% with semaglutide and -2.4% with placebo, for a difference of -12.44% (P <.001). Also, 86.4% of participants in the semaglutide group achieved ≥5% bodyweight reduction, vs 31.5% of the placebo group. (p<.001). Regarding adverse events and drug discontinuation, 9.8% of patients in the semaglutide group and 6.4% in the placebo group reported serious adverse events, with more serious GI disorders (1.4% in semaglutide vs 0% in placebo).
Bottom Line: This was a positive study. Semaglutide was associated with a large reduction in weight compared with placebo when used as an adjunct to lifestyle interventions. This treatment effect is larger than currently approved weight loss medications.
Hotcakes rating: Half Stack (B) rating from Adnan
Question: What are the comparative effectiveness and harms of metronidazole plus a fluoroquinolone versus amoxicillin-clavulanate in treating outpatient diverticulitis?
Comparison: This was an active-comparison, new-user (ACNU!), retrospective cohort study comparing the use of metronidazole/fluoroquinolone with amoxicillin-clavulanate for treatment of uncomplicated acute diverticulitis. Outcomes included inpatient admission for diverticulitis, urgent surgery, or Clostridioides difficile infection (CDI) in the year after diagnosis. The authors also assessed risk for elective surgery within 3 years of diagnosis of diverticulitis.
Results: Metronidazole/fluoroquinolone was used 89% of the time in the MarketScan cohort (median age 52) and 86.7% of the time in the Medicare cohort (median age 73). In the MarketScan group, there was no difference between treatment groups in 1-year hospital admission risk [risk difference, 0.1%, 95% CI, -0.3-0.6], 1-year urgent surgery risk [risk difference, 0.0%, 95% CI, -0.1 to 0.1], or 3-year elective surgery risk [risk difference, 0.2%, 95% CI -0.3-0.7]. There was also no difference in the 1-year risk of CDI between treatment groups.
Results were similar in the Medicare group, except the risk of CDI was significantly higher for metronidazole/fluoroquinolone (1.2%) compared to the amoxicillin-clavulanate (0.6%), with a difference of 0.6 percentage points [CI 0.2-1.0], and a number needed to treat to harm calculated as 167.
Bottom Line: In two large nationwide cohorts, there was no significant difference in inpatient admissions, urgent surgeries, and elective surgeries between patients treated with metronidazole and a fluoroquinolone versus those treated with amoxicillin-clavulanate. In the Medicare cohort, treatment with metronidazole/fluoroquinolone was associated with a higher risk of CDI.
Hotcakes rating: Half-stack (B-rating) from Paul. It has all the limits of chart-mining studies but was incredibly thoughtful, well-designed, and compelling enough to change practice.
Black Box Warning on FQ – FDA July 2016
Question: What is the optimal timing of surgery after SARSCoV2 infection to reduce 30-day post-op mortality (primary outcome) and pulmonary complications (secondary outcome)? This study was funded by the NIHR, Global Research Group.
Comparison: This was an observational, international, multicenter prospective cohort study with 140,231 patients of all ages undergoing surgery of which 3,127 (2.2%) patients had SARSCoV2 as confirmed by labs, imaging, or clinical diagnosis. Outcomes were assessed based on timing from diagnosis of SARSCoV2 infection to date of surgery (0-2 weeks, 3-4 weeks, 5-6 weeks, or ≥7 weeks).
Results: Compared with patients who did not have a pre-operative diagnosis of COVID19, thirty-day post-op mortality was significantly elevated from zero through six weeks (OR ranging 3.6-4.1) among patients with a history of SARSCoV2 infection, but not for those more than 7 weeks since diagnosis. Adjusted 30-day mortality in patients without SARSCoV2 was 1.5% (95%CI 1.4-1.5) and was similar in patients with SARSCoV2 beyond 7 weeks after diagnosis. Patients with ongoing SARSCoV2 symptoms beyond 7 weeks also had increased 30-day post-op mortality. Post-op pulmonary complications were increased in all SARSCoV2 patients especially in weeks zero through six. Older sicker patients had higher mortality.
Bottom Line: This study suggests that patients should wait at least 7 weeks after confirmed SARSCoV2 infection before undergoing elective surgery to mitigate post-op mortality and pulmonary complications. Those who still have symptoms beyond 7 weeks should wait until symptoms resolve.
Hotcakes rating: B – Half Stack
DARK tv series (Netflix) -Adnan’s pick
Listeners will review recent practice-changing articles on GLP1 agonists for weight loss, amoxicillin-clavulanate for diverticulitis, and perioperative risk after COVID19 infection
After listening to this episode listeners will…
Drs. Khan, Watto, Williams, and Ganatra report no relevant financial disclosures.
Watto MF, Ganatra RB, Khan A, Williams PN. “#264 Hotcakes: Semaglutide for weight loss, Abx for Diverticulitis, Periop COVID19”. The Curbsiders Internal Medicine Podcast. http://thecurbsiders.com/episode-list Final publishing date March 29, 2021.
The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org and search for this episode to claim credit.
Got feedback? Suggest a Curbsiders topic. Recommend a guest. Tell us what you think.
We love hearing from you.
Yes, you can now join our exclusive community of core faculty at Kashlak Memorial Hospital along with all the perks:
Close this notice to consent.
Good Morning, I was listening to this specific "Hotcakes" version to apply the articles to a case study assignment that I am writing. In the last 10 days I have seen 2 post-CoVid patients - both had C-19 (covid-19) in November of 2020, never really 'felt better' both had readmission to inpatient care due to right flank pain, both diagnosed with pancreatic cancer. Is there a relation? One patient was a 59 y/o Female & the other 74 y/o Male. No other SES or vocational simililarties. Thanks so much for what you do, I have learned so much! Your podcast is a motivator for my morning walks. Christine